Sitemap| The Best Is Yet To Come (2/27/2011) |
|
The Best Is Yet To Come Thank you for visiting Cellceutix Corporation's official website. My name is Leo Ehrlich,CPA Chief Executive Officer of Cellceutix. There are a great many things happening at our Company. Our most recent announcement concerned our flagship anti-cancer compound, Kevetrin, which reactivates p53, the “Guardian Angel of the Human Genome.” Potentially, this is not only a major breakthrough for Cellceutix, but for the world of oncology, as p53 has long been believed to possibly hold a key to unlocking the next generation of cancer therapies. p53 has a deserved nickname as it functions to activate the life-saving actions of other proteins within our bodies. In more than 50% of all cancers, p53 is mutated and not performing properly to help protection of our cells, allowing various malignancies the opportunity to rapidly grow and multiply. Kevetrin has been shown to reactivate P53, often to baseline status, which, in turn, activates other proteins that destroy or significantly slow the growth of cancer cells. This is something that scientists worldwide, at pharmaceutical companies both large and small, have been striving for, but to the best of our knowledge, have not yet achieved. While we believe that this discovery is revolutionary, it is still only one of many compounds in our pipeline . We at Cellceutix believe that we are different from other developmental biotech firms due to the strength of our drugs in development. Our foundation has three major goals:
Kevetrin addresses our first goal. KM-133, or Prurisol, as it is also known, is another compound being developed as a treatment for psoriasis and has thus far shown in animal studies, a significant impact on the disease. It is the focus of our second goal in addressing emerging markets. I expect to update you more about this in the coming weeks. Regarding our third goal, KM-391 has already received a great deal of media attention as it is one of the few drugs that is targeting the core issues of autism rather than merely treating the symptoms. Early pre-clinical research is, once again, proving extremely promising. At Cellceutix, we feel that optimism and hard work is the only option. Our optimism is based on our team which consists of some of the brightest minds in drug development. They have a proven track record of success being involved in the development of drugs which have generated billions of dollars in revenues while providing a better standard of life for patients in need. There is a reason that we have come together as a team and we do not intend to fail. I’d like to personally welcome everyone to Cellceutix Corporation and urge you to sign up on our home page for news alerts. If you have any questions, do not hesitate to contact us immediately. Thank you, Leo Ehrlich |